Executive Panel Discussion | BioPharma CEO Fireside Chat

Alliance management is a dynamic discipline–Some alliance managers build decades long careers in the field, while others leverage their experience to take on new roles. Join us for a fireside chat with two former alliance leaders who recently joined the C-suite within their organizations–Krishnan Viswanadham, president and COO of Be Bio, and Andy Eibling, president and CEO of GeniPhys. These biopharma executives will share their career path stories, outline their views on the alliance management skills that help them the most in their current roles, and share their unique perspectives on how alliance management now looks from the C-suite.

Moderator:

Brooke Paige, CSAP
Digital Alliances
Novartis

Brooke Paige is a digital therapeutics and external innovation pioneer, and one of the first alliance managers in the biopharma industry. After writing her business school thesis in "The optimal management and structure of a pharmaceutical alliance," Brooke became a global practitioner in the space. Prior to her current role, Brooke joined Pear Therapeutics as Employee #42, where she served as Vice President, Alliance Management. Brooke was Chairman of the Board for ASAP, the Association of Strategic Alliance Professionals, for six years, and remains active as Chairman Emeritus. She is most proud of having been hired by two different former alliance partners to represent their interests in alliances–including her current employer, Novartis, where Brooke manages the organization's digital collaborations.

Panelists:

Dr. Krishnan Viswanadhan
President & Chief Operating Officer
Be Biopharma

Dr. Krishnan Viswanadhan is a biopharmaceutical executive with over 20 years of broad cross-functional experience in advancing new medicines for patients with serious and life-threatening diseases. Krishnan is current President and Chief Operating Officer at Be Biopharma, a leader in engineered B cells as a new category of medicines for patients with serious diseases.

Prior to Be Bio, Krishnan was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb where he was responsible for overseeing the integrated cell therapy franchise strategy across the enterprise including building core capabilities and key investments to support long term growth. He oversaw the teams responsible for the development, approval, and life cycle management of Breyanzi, a CD19 CAR T and Abecma, the first BCMA CAR T therapy.

Prior to BMS, Krishnan was Vice President, Business Development and Global Alliances at Celgene Corporation responsible for managing the portfolio of partnerships and equity investments. Prior to Celgene, Krishnan had roles in large and small companies in regulatory strategy.

Dr. Viswanadhan is a registered Pharmacist and received his Doctor of Pharmacy degree from Rutgers University and holds a Master of Business Administration degree from Cornell University.

Krishnan currently serves the board as a non-executive director of JW Therapeutics, a leading cell therapy company in China.